It is the long term goal of this research to develop a method of orderly segmenting the human genome into 1-50 Mb fragments. This objective can be achieved by streamlining the screening process of hybrid clones generated by chromosome fragment gene transfer (CFGT). The most expeditions screening process is one which includes a dominant selectable marker near the locus of interest. Homologous recombination will be used to direct a dominant selectable marker to a specific chromosomal location allowing the targeted to become phenotypically selectable. Cells containing a correctly targeted dominant marker are an ideal donor source for Goss-Harris hybrids. The transgenomes produced by this approach will be valuable reagents for molecular and medical genetic research. They will allow for a rapid means of saturating a locus with genetic markers. In addition, the resulting enrichment of a targeted genetic disease locus will facilitate the identification of the responsible defect. At the genome level, a set of targeting vectors, each directed to chromosomal locations separated by 10-20 Mb, could generate an ordered set of """"""""transgenome"""""""". These reagents would enhance current and future human genome mapping efforts.
| Williams, Stephen R; Hsu, Fang-Chi; Keene, Keith L et al. (2016) Shared genetic susceptibility of vascular-related biomarkers with ischemic and recurrent stroke. Neurology 86:351-9 |
| Garcia-Closas, Montserrat; Ye, Yuanqing; Rothman, Nathaniel et al. (2011) A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. Hum Mol Genet 20:4282-9 |
